DKK1 and breast carcinoma: In breast cancer, CAFs expressing Dickkopf‐1 (DKK1)—a Wnt/β‐catenin inhibitor linked to disease progression—attenuate NK cell activation and cytotoxicity by downregulating AKT/ERK/S6 phosphorylation [85].